Cargando…

Hypertension and Dyslipidaemia in Argentina: Patient Journey Stages

Cardiovascular disease (CVD) leads to one-third of all deaths in Argentina. To implement patient-centric strategies for reducing CVD burden, available data on hypertension and hypercholesterolemia patients at different stages of their journey: awareness, screening, diagnosis, treatment, adherence, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadler, Alberto E, Belcastro, Fernando, Yarleque, Carlos R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572553/ https://www.ncbi.nlm.nih.gov/pubmed/36258799 http://dx.doi.org/10.2147/IJGM.S358476

Ejemplares similares

Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey
por: Faria-Neto, Jose Rocha, et al.
Publicado: (2022)

Angina due to hypertension and dyslipidaemia
por: Fox, Kim
Publicado: (2019)

Nutraceuticals in Paediatric Patients with Dyslipidaemia
por: Banderali, Giuseppe, et al.
Publicado: (2022)

Diabetic dyslipidaemia
por: C. Thambiah, Subashini, et al.
Publicado: (2021)

Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica
por: Gordon, Lorenzo, et al.
Publicado: (2010)

Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity
por: Moraba, Mpho, et al.
Publicado: (2013)

Treatment of Dyslipidaemia in Children
por: Fiorentino, Riccardo, et al.
Publicado: (2021)

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review
por: Cramer, J A, et al.
Publicado: (2008)

Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
por: Penson, Peter E., et al.
Publicado: (2021)

Management of hypertension and dyslipidemia in Mexico: evidence, gaps, and approach
por: Morales-Villegas, Enrique C., et al.
Publicado: (2023)

Fixed Combination for the Treatment of Dyslipidaemia
por: Ferri, Nicola, et al.
Publicado: (2023)

HIV: how to manage dyslipidaemia in HIV
por: Lee, Daniel
Publicado: (2022)

Pathophysiology of diabetic dyslipidaemia: where are we?
por: Vergès, Bruno
Publicado: (2015)

New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection—Systematic Review
por: Wrona, Marysia, et al.
Publicado: (2022)

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study
por: Iyengar, S. S., et al.
Publicado: (2020)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Established and Emerging Approaches for the Management of Dyslipidaemia
por: Norata, Giuseppe Danilo
Publicado: (2012)

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)
por: Raal, Frederick J, et al.
Publicado: (2013)

Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review
por: Alhyas, Layla, et al.
Publicado: (2011)

Present and Future of Dyslipidaemia Treatment—A Review
por: Merćep, Iveta, et al.
Publicado: (2023)

The year in dyslipidaemia 2008 /
Publicado: (2009)

The year in dyslipidaemia 2007
Publicado: (2008)

Dyslipidaemia in Rheumatological Autoimmune Diseases
por: Toms, Tracey E, et al.
Publicado: (2011)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Lorenzatti, Alberto J, et al.
Publicado: (2020)

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
por: Boccara, Franck, et al.
Publicado: (2017)

The year in dyslipidaemia : version en español 2009-2010 /
Publicado: (2010)

The year in dyslipidaemia 2005-2006
Publicado: (2006)

Ageing, obesity, dyslipidaemia, and hospital-room hypertension are clinical risk factors relating to pre-anaesthesia hypertension
por: Mizuno, Ju, et al.
Publicado: (2020)

Statin Therapy and the Assessment of Hepatoprotection in Patients with Dyslipidaemia
por: Beznă, Marinela, et al.
Publicado: (2023)

Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
por: Abbas, Ahmed, et al.
Publicado: (2012)

New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
por: Merćep, Iveta, et al.
Publicado: (2022)

Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
por: Colletti, Alessandro, et al.
Publicado: (2022)

Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities
por: O’Brien, Stephen T., et al.
Publicado: (2021)

The Role of the Circadian Rhythm in Dyslipidaemia and Vascular Inflammation Leading to Atherosclerosis
por: Csoma, Balazs, et al.
Publicado: (2023)

Potential curing and beneficial effects of Ooitabi (Ficus pumila L.) on hypertension and dyslipidaemia in Okinawa
por: Suzuki, K., et al.
Publicado: (2020)

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys
por: Bays, H E, et al.
Publicado: (2007)

Antiretroviral Therapy and Dyslipidaemia: Unlocking the Code
por: Mallon, Patrick W. G
Publicado: (2006)

Adverse effects of the ‘Noakes’ diet on dyslipidaemia
por: Schamroth, C
Publicado: (2014)

Emerging Strategies for the Management of Atherogenic Dyslipidaemia
por: Agarwala, Anandita, et al.
Publicado: (2020)

Association of dyslipidaemia with osteoporosis in postmenopausal women
por: Zhang, Lingnan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9b8g71skuufa4pjid4da08se2q